Nanobiotix SA
5NR
Company Profile
Business description
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
Contact
60 Rue de Wattignies
Paris75012
FRAT: +33 140260470
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
103
Stocks News & Analysis
stocks
Does SpaceX’s sky-high valuation make sense?
SpaceX’s $1.5 trillion valuation looks expensive and risky, but not irrational.
stocks
ASX healthcare leader sees further cuts to fair value
Fiercer competition expected to squeeze margins.
stocks
Avoid this overpriced ASX share
This ASX share is 84% overvalued and lacks a sustainable competitive advantage.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,976.80 | 44.30 | 0.50% |
| CAC 40 | 8,041.81 | 126.45 | 1.60% |
| DAX 40 | 23,640.03 | 328.60 | -1.37% |
| Dow JONES (US) | 47,417.27 | 289.24 | -0.61% |
| FTSE 100 | 10,353.77 | 58.47 | -0.56% |
| HKSE | 25,898.76 | 490.30 | 1.93% |
| NASDAQ | 22,716.13 | 19.03 | 0.08% |
| Nikkei 225 | 55,025.37 | 776.98 | 1.43% |
| NZX 50 Index | 13,293.13 | 194.30 | 1.48% |
| S&P 500 | 6,775.80 | 5.68 | -0.08% |
| S&P/ASX 200 | 8,743.50 | 39.10 | 0.45% |
| SSE Composite Index | 4,133.43 | 10.29 | 0.25% |